Hba1c

A once-weekly basal insulin conferred noninferior reductions in HbA1c among insulin-naive adults with type 2 diabetes and those who receive multiple daily insulin injections, according to top-line results from two phase 3 trials.

Testosterone therapy did not improve cardiometabolic measures for older men with obesity and hypogonadism receiving lifestyle intervention, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Adults who previously used an obesity medication before receiving semaglutide lost less body weight at 12 months than those who did not use an obesity medication before semaglutide, according to study findings.

Researchers found that middle-aged adults who adhered closest to a healthy plant-based diet had a reduced risk for developing diabetes.

A once-weekly basal insulin conferred similar changes in HbA1c and time in range as once-daily insulin glargine among adults with type 1 and type 2 diabetes in three phase 2 trials, according to a speaker.

Providers should use both HbA1c values and continuous glucose monitoring data to manage diabetes and prevent complications, though HbA1c should remain the standard for diagnosing diabetes, according to two speakers.

Using a pod-based automated insulin delivery system can provide glycemic benefits for people with type 2 diabetes, according to a speaker at the International Conference on Advanced Technologies & Treatments for Diabetes.

Adults with type 2 diabetes and obesity who underwent bariatric surgery were more likely to achieve diabetes remission at 7 years than those treated with medication or lifestyle intervention, according to study findings published in JAMA.

Adults with type 1 diabetes who received tirzepatide in a real-world setting had reductions in HbA1c and body weight at 3 months that were sustained for up to 8 months, according to study data.

The risk for developing chronic kidney disease or cardiovascular disease is much lower among adults who achieve type 2 diabetes remission compared with those who do not, according to a post hoc analysis of the Look AHEAD trial.